What’s curious about this map? It shows the disparity between the hotspots of high disease prevalence for patients with decompensated liver disease and areas which have been historically research active. It is well documented that patients with #liverdisease are underserved. Developing new treatments that improve the outcome for this patient group remains an unmet area of clinical need. As an active CRO in #hepatology #clinicaltrials, we are delighted to collaborate with the UK hepatology community including Oliver Tavabie, Gautam Mehta, Rajiv Jalan, Daniel Green and the UK-Chronic Liver Failure network (UK-CLIF), on a review discussing the challenges and opportunities for innovating hepatology trials in the UK. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY ⇒ We propose a number of innovations in clinical trial design to improve access to clinical trials for patients, clinicians and investigators alike. ⇒ We highlight the importance of agreeing and implementing standards of care for this patient group, which should not just improve clinical outcomes but reduce heterogeneity in standard of care/placebo cohorts. ⇒ We discuss the potential role of collaboration with industry to improve the delivery of clinical trials. ⇒ We discuss the importance of ensuring the development of the next generation of investigators to ensure sustainability to this model of working. You can read the full review on the PHARMExcel website 👉 https://lnkd.in/dkg42TwU #Heptology #ClinicalTrials #Gastroenterology #LiverDisease #FrontlineGastroenterology #ClinicalResearch # Yvanne Enever
Concur that as an active CRO in #hepatology #clinicaltrials, we are delighted to collaborate through the UK-Chronic Liver Failure network (UK-CLIF), with, Gautam Mehta , Oliver Tavabie and Rajiv Jalan on a review discussing the challenges and opportunities for innovating hepatology trials in the UK.
Co-Founder @ RWR-Regs | Real World Evidence Solutions | Mental Health Advocate
2moThis map only shows England...